Results 21 to 30 of about 178,910 (213)
Headache, 2022 Assessing mechanical pain thresholds from trigeminal, cervical, and distal pain‐free areas during the four phases of a migraine cycle in patients with episodic migraine (EM).
Stefano Di Antonio +7 more
semanticscholar +1 more source
A volumetric magnetic resonance imaging study in migraine
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021 Background Although migraine phenotype has been widely described, the explanation of migraine pathophysiology still has a gap that might be partly bridged by neuroimaging investigations.
Laila Elmously Naguib +2 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials.
Bo Hu +9 more
semanticscholar +1 more source
Brain Sciences, 2020 The white matter state in migraine has been investigated using diffusion tensor imaging (DTI) measures, but results using this technique are conflicting.
Álvaro Planchuelo-Gómez +5 more
doaj +1 more source
Functional connectivity and structural changes of thalamic subregions in episodic migraine
The Journal of Headache and Pain, 2022 Background The thalamus plays a crucial role in transmitting nociceptive information to various cortical regions involving migraine-related allodynia and photophobia.
Ying Yang +8 more
semanticscholar +1 more source
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Cephalalgia, 2020 Objective To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine.
M. Ashina +8 more
semanticscholar +1 more source
Episodic Acute Migraine Treatment [PDF]
Headache: The Journal of Head and Face Pain, 2014 The ideal migraine medication would provide rapid “one and done” treatment of migraine for all sufferers. Unfortunately, no such intervention is available. While most people respond to triptans or DHE, some will need to combine these with an NSAID, or will choose to use an NSAID alone because of personal preference or for medical reasons.
openaire +2 more sources
Neurology and Therapy, 2023 Introduction Eptinezumab is a humanized IgG1 immunoglobulin monoclonal antibody administered intravenously as a preventative migraine treatment. Previously conducted randomized, double-blind, placebo-controlled trials exhibited significant reductions in ...
Yazan Bader +5 more
doaj +1 more source
Defining the Differences Between Episodic Migraine and Chronic Migraine [PDF]
Current Pain and Headache Reports, 2011 Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Population-based studies have shown that those with CM demonstrate higher individual and societal burden because they are significantly more disabled than those with EM and have greater impaired quality of life both ...
Katsarava, Zaza +3 more
openaire +2 more sources
Contemporary Clinical Trials Communications, 2020 Introduction: Approximately 15% of the US population experiences migraine, with women afflicted three times as often as men. While medications are often used as first-line treatments, up to 50% of people with migraine pursue complementary and integrative
P.M. Wayne +8 more
doaj +1 more source